RSS

methamphetamine

The first patient has been enrolled by InterveXion in STAMPOUT — the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200 — the news of which Catalent Pharma Solutions has welcomed. Read more

News